Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478062 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00478062 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 1 participants.
The verdict
NCT00478062, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a tumor antigen may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects and how well vaccine therapy works in treating patients who have received first-line therapy for Hodgkin's lymphoma.
Interventions
- PROCEDURE adjuvant therapy
- BIOLOGICAL Hodgkin's antigens-GM-CSF-expressing cell vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00478062
The ClinicalTrials.gov registry entry for NCT00478062 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which adjuvant therapy is the first listed.
NCT00478062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00478062 about?
NCT00478062 is a clinical study titled "Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma". RATIONALE: Vaccines made from a tumor antigen may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects and how well vaccine therapy works in treating patients who have received first-line therapy for Hodgkin's lymphoma.
What is the current status of trial NCT00478062?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2007-04. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00478062?
The interventions under investigation include: adjuvant therapy (PROCEDURE), Hodgkin's antigens-GM-CSF-expressing cell vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00478062?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.